A493280 Share Price Performance
₩24,050.00
-79950.00 (-76.88%)
Price ₩24,050.00
Share Pricen/a
IMBiologics Corp. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
A493280 Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
IMBiologics Corp. Key Details
About A493280
- Founded
- 2020
- Employees
- n/a
- CEO
- WebsiteView website
IMBiologics Corp., a biotechnology company, engages in developing immunomodulatory antibody therapeutics to treat autoimmune diseases and cancer. The company uses Optimal Antibody Modality Manufacturing Technology (IM-OpDECon) for developing differentiated treatments for autoimmune diseases and immuno-oncology based on immuno-modulatory biologics. Its products include IMB-101, a bispecific therapeutic antibody that targets OX40L and TNF to modulate pathological immune mechanisms mediating Th1/Th17 immune responses; IMB-102; IMB-201, an antibody-drug conjugate that targets HLA-G, a tumor-specific antigen; IMB-402, a concept anticancer vaccine bispecific antibody that utilizes the ePENDY (IgM-Agonist) modality to activate cancer cell-specific T cells. IMBiologics Corp. was founded in 2020 and is based in Suwon-si, South Korea.
